Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace Inc (NPCE) is a pioneering medical technology company developing brain-responsive neuromodulation systems for epilepsy treatment. This page serves as the definitive source for official company announcements, financial updates, and clinical progress reports.
Access timely updates on NPCE's innovative RNS System, including FDA regulatory milestones, partnership developments with leading epilepsy centers, and peer-reviewed clinical study results. Investors will find earnings reports and strategic initiatives, while healthcare professionals can track real-world treatment outcomes and technological refinements.
Our curated news collection features:
- Quarterly financial performance updates
- RNS System enhancement announcements
- Clinical trial data publications
- Regulatory clearance milestones
- Research collaborations with medical institutions
Bookmark this page for structured access to NPCE's evolving role in neurotechnology and epilepsy care innovation.
NeuroPace, Inc. (Nasdaq: NPCE) will release its financial results for Q1 2022 on May 12, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, accessible via phone or webcast on their website. NeuroPace specializes in medical devices for epilepsy treatment, with its RNS System being the first brain-responsive platform delivering timely, personalized therapies. This innovative approach aims to improve care for drug-resistant epilepsy patients and potentially others with brain disorders, enhancing treatment outcomes.
NeuroPace, Inc. (Nasdaq: NPCE) reported a 10% increase in total revenue, reaching $45.2 million for 2021, driven by a 20% rise in initial implant revenue. The fourth quarter revenue was $11.0 million, a 2% increase year-over-year. However, replacement implant revenue declined 19% in Q4. The company received FDA approval for a pivotal study in drug-resistant epilepsy and increased battery life for its RNS System. For 2022, guidance estimates total revenue between $45 million and $48 million.
NeuroPace, Inc. (Nasdaq: NPCE) announced it will report its financial results for Q4 and full year 2021 on March 10, 2022, post-market. A conference call will follow at 1:30 PM PT. Interested investors can join the call by dialing (844) 955-2173 or (914) 987-7949. CEO Mike Favet and other executives will also present at the SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:00 AM PT. NeuroPace specializes in innovative medical devices for epilepsy treatment, with its RNS System being the first brain-responsive platform for real-time seizure management.
NeuroPace, Inc. (Nasdaq: NPCE) reported preliminary unaudited revenue for Q4 and full-year 2021. Q4 revenue is expected at $11.0 million, a 2% increase year-over-year, with initial implant revenue at $8.5 million (10% growth). However, replacement implant revenue declined by 19% to $2.5 million. Full-year revenue is anticipated at $45.2 million, up 10% from 2020, driven by $33.7 million from initial implants (20% growth), but replacement implant revenue dropped 12% to $11.5 million. NeuroPace plans to present detailed financial results in March 2022.
NeuroPace, a medical device company focused on epilepsy treatment, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference. CEO Mike Favet, CFO Rebecca Kuhn, and General Counsel Irina Ridley will present virtually on January 12, 2022, at 8:15 AM PT / 11:15 AM ET. A live webcast and subsequent archived recording will be available for 90 days on the company's website. NeuroPace's RNS System offers a unique, brain-responsive platform aimed at improving the lives of epilepsy patients by delivering real-time treatment.
NeuroPace, a medical device company focused on epilepsy treatment, reported Q3 2021 revenue of $10.3 million, a 19% decrease from last year. Initial implant revenue was $7.8 million, down 15%, influenced by COVID-19 disruptions. The company received IDE approval for a study on drug-resistant epilepsy and submitted a supplement for extending battery life claims of its RNS neurostimulator by two years. Operating expenses increased to $13.8 million, leading to a net loss of $8.1 million. Full-year guidance estimates total revenue between $44 million to $44.5 million.
NeuroPace has received FDA Investigational Device Exemption for its RNS® System to study treatment of drug-resistant idiopathic generalized epilepsy (IGE) in patients aged 12 and older. The NAUTILUS study will be the first in the U.S. to evaluate brain-responsive neuromodulation for IGE treatment, starting patient enrollment in 2022. The RNS System aims to improve life quality by monitoring and responding to patients' unique brain patterns. Previously, it received Breakthrough Device Designation from the FDA for this condition.
NeuroPace, Inc. (Nasdaq: NPCE) announced it will release its third-quarter 2021 financial results on November 10, 2021, after market close. Following the results, the company's management will host a conference call at 1:30 p.m. PT, available via dial-in or through a live webcast on their website. NeuroPace specializes in medical devices aimed at treating epilepsy, utilizing its innovative RNS System which provides personalized neuromodulation therapy to patients with drug-resistant seizures.
NeuroPace (Nasdaq: NPCE) announced on October 19, 2021, the appointment of Lisa Andrade to its Board of Directors, effective November 1, 2021. Andrade brings over 25 years of experience in the medtech sector and is currently the CEO of M33. She has held key positions at St. Jude Medical and possesses expertise in strategy, product development, and marketing. Additionally, Evan Norton is resigning from the board. Andrade expressed excitement about contributing to NeuroPace’s mission to transform epilepsy care with its RNS® System, approved for drug-resistant focal epilepsy.
MOUNTAIN VIEW, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) announced participation in three significant healthcare conferences. The schedule includes:
- Wells Fargo Virtual Healthcare Conference on September 10, 2021, at 9:20 a.m. ET.
- Morgan Stanley Global Healthcare Conference on September 14, 2021, at 3:30 p.m. ET.
- Baird Global Healthcare Conference on September 15, 2021, at 2:35 p.m. ET.
Live audio will be available on the company’s website, with archives accessible for at least 90 days post-event.